Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Organon & Co

7XP
Current price
14.21 EUR -0.29 EUR (-2.03%)
Last closed 15.31 USD
ISIN US68622V1061
Sector Healthcare
Industry Drug Manufacturers - General
Exchange Frankfurt Exchange
Capitalization 4 130 925 824 USD
Yield for 12 month +32.89 %
1Y
3Y
5Y
10Y
15Y
7XP
21.11.2021 - 28.11.2021

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey. Address: 30 Hudson Street, Jersey City, NJ, United States, 07302

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

22.86 USD

P/E ratio

3.1762

Dividend Yield

7.45 %

Current Year

+6 263 000 000 USD

Last Year

+6 174 000 000 USD

Current Quarter

+1 582 000 000 USD

Last Quarter

+1 607 000 000 USD

Current Year

+3 748 000 000 USD

Last Year

+3 880 000 000 USD

Current Quarter

+923 000 000 USD

Last Quarter

+939 000 000 USD

Key Figures 7XP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 764 000 000 USD
Operating Margin TTM 24.65 %
PE Ratio 3.1762
Return On Assets TTM 7.91 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 22.86 USD
Revenue TTM 6 408 999 936 USD
Book Value 1.91 USD
Revenue Per Share TTM
Dividend Share 1.12 USD
Quarterly Revenue Growth YOY 4.1 %
Dividend Yield 7.45 %
Gross Profit TTM 3 889 000 000 USD
Earnings per share 5.05 USD
Diluted Eps TTM 5.05 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY 508.1 %
Profit Margin 20.3 %

Dividend Analytics 7XP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

30 %

Dividend History 7XP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 1.12
Ex Dividend Date 12.11.2024
Forward Annual Dividend Yield 6.98 %
Last Split Factor
Payout Ratio 27.38 %
Last Split Date
Dividend Date 12.12.2024

Stock Valuation 7XP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 3.1762
Forward PE 5.0302
Enterprise Value Revenue 1.8906
Price Sales TTM 0.6446
Enterprise Value EBITDA 7.7722
Price Book MRQ 8.3792

Financials 7XP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 7XP

For 52 weeks

10.38 USD 23.1 USD
50 Day MA 18.76 USD
Shares Short Prior Month 7 764 700
200 Day MA 19.33 USD
Short Ratio 5.65
Shares Short 12 531 724
Short Percent 6.49 %